Joshua D Stein1, Taylor S Blachley, David C Musch. 1. Department of Ophthalmology and Visual Sciences, W.K. Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan. Electronic address: jdstein@med.umich.edu.
Abstract
PURPOSE: To assess the extent to which incidence rates calculated for common ocular diseases by using claims data may be overestimated according to the length of the disease-free look-back period used in the analysis. DESIGN: Retrospective longitudinal cohort analysis. METHODS: Billing records of 2457 persons continuously enrolled for 11 years in a managed-care network were searched for International Classification of Diseases (ICD-9-CM) diagnoses of cataract, open-angle glaucoma (OAG), nonexudative age-related macular degeneration (ARMD), and nonproliferative diabetic retinopathy (NPDR) at eye-care visits in the first half of 2001, the second half of 2010, and 2011. For each condition, incidence rates calculated by using "look-back" periods ranging from 0.5-9 years were compared with best estimates from a gold-standard period of 9.5 years. RESULTS: With a 1-year disease-free look-back period, incidence was overestimated by 260% for cataract, 135% for OAG, 209% for ARMD, and 300% for NPDR. Expanding the disease-free look-back period to 3 years resulted in a reduction of incidence overestimation to 40% for cataract, 14% for OAG, 45% for ARMD, and 100% for NPDR. A 5-year look-back period yielded incidence rates that were overestimated by <30% for all 4 conditions. CONCLUSIONS: In our claims-data analysis of 4 common ocular conditions, a disease-free interval ≤1 year insufficiently distinguished newly diagnosed from pre-existing disease, resulting in grossly overestimated incidence rates. Using look-back periods of 3-5 years, depending on the specific diagnosis, yielded considerably more accurate estimates of disease incidence.
PURPOSE: To assess the extent to which incidence rates calculated for common ocular diseases by using claims data may be overestimated according to the length of the disease-free look-back period used in the analysis. DESIGN: Retrospective longitudinal cohort analysis. METHODS: Billing records of 2457 persons continuously enrolled for 11 years in a managed-care network were searched for International Classification of Diseases (ICD-9-CM) diagnoses of cataract, open-angle glaucoma (OAG), nonexudative age-related macular degeneration (ARMD), and nonproliferative diabetic retinopathy (NPDR) at eye-care visits in the first half of 2001, the second half of 2010, and 2011. For each condition, incidence rates calculated by using "look-back" periods ranging from 0.5-9 years were compared with best estimates from a gold-standard period of 9.5 years. RESULTS: With a 1-year disease-free look-back period, incidence was overestimated by 260% for cataract, 135% for OAG, 209% for ARMD, and 300% for NPDR. Expanding the disease-free look-back period to 3 years resulted in a reduction of incidence overestimation to 40% for cataract, 14% for OAG, 45% for ARMD, and 100% for NPDR. A 5-year look-back period yielded incidence rates that were overestimated by <30% for all 4 conditions. CONCLUSIONS: In our claims-data analysis of 4 common ocular conditions, a disease-free interval ≤1 year insufficiently distinguished newly diagnosed from pre-existing disease, resulting in grossly overestimated incidence rates. Using look-back periods of 3-5 years, depending on the specific diagnosis, yielded considerably more accurate estimates of disease incidence.
Authors: Joshua D Stein; Denise S Kim; Leslie M Niziol; Nidhi Talwar; Bin Nan; David C Musch; Julia E Richards Journal: Ophthalmology Date: 2011-02-18 Impact factor: 12.079
Authors: Jonathan C Javitt; Zhiyuan Zhou; Maureen G Maguire; Stuart L Fine; Richard J Willke Journal: Ophthalmology Date: 2003-08 Impact factor: 12.079
Authors: David S Friedman; Harry A Quigley; Laurie Gelb; Jason Tan; Jay Margolis; Sonali N Shah; Elizabeth E Kim; Thom Zimmerman; Steven R Hahn Journal: Invest Ophthalmol Vis Sci Date: 2007-11 Impact factor: 4.799
Authors: C Quantin; E Benzenine; M Hägi; B Auverlot; M Abrahamowicz; J Cottenet; E Fournier; C Binquet; D Compain; E Monnet; A M Bouvier; A Danzon Journal: J Cancer Epidemiol Date: 2012-06-26
Authors: Paula Anne Newman-Casey; Taylor Blachley; Paul P Lee; Michele Heisler; Karen B Farris; Joshua D Stein Journal: Ophthalmology Date: 2015-08-25 Impact factor: 12.079
Authors: Durga S Borkar; Lucia Sobrin; Rebecca A Hubbard; John H Kempen; Brian L VanderBeek Journal: Ophthalmic Epidemiol Date: 2018-12-06 Impact factor: 1.648
Authors: Thasarat Sutabutr Vajaranant; Roberta M Ray; Louis R Pasquale; Julie A Mares; Robert Ritch; Emily W Gower; Mary N Haan; Rebecca D Jackson; Pauline M Maki Journal: Am J Ophthalmol Date: 2018-08-04 Impact factor: 5.258
Authors: Lucia Sobrin; Yinxi Yu; Samuel Han; Gayatri Susarla; John H Kempen; Rebecca A Hubbard; Brian L VanderBeek Journal: Graefes Arch Clin Exp Ophthalmol Date: 2021-05-29 Impact factor: 3.535
Authors: Lucia Sobrin; Yinxi Yu; Samuel Han; Gayatri Susarla; John H Kempen; Rebecca A Hubbard; Brian L VanderBeek Journal: Ocul Immunol Inflamm Date: 2021-03-08 Impact factor: 3.728
Authors: Joshua D Stein; Nidhi Talwar; Jae H Kang; Olivia I Okereke; Janey L Wiggs; Louis R Pasquale Journal: PLoS One Date: 2015-04-13 Impact factor: 3.240